SV2017

Suma Vupputuri, PhD, MPH, FAHA

Research Scientist

Suma.Vupputuri@kp.org

Education:

PhD, Tulane University School of Public Health and Tropical Medicine, 2001
MPH, Tulane University School of Public Health and Tropical Medicine, 1996

Suma Vupputuri is an epidemiologist with a focus on the etiology, prevention, and treatment of chronic disease. Her substantive areas of interest include heart disease, diabetes, and chronic kidney disease epidemiology, as well as health services and health disparities research. Dr. Vupputuri also worked at KP for over 4 years in the Georgia region and has experience with many types of studies including observational, pragmatic trials, and multi-site surveillance/data systems for studying trends in cardiovascular disease and diabetes.

Dr. Vupputuri has worked in a variety of different health research settings and has broad experience on how real-world health data is collected, managed, and processed in and across different systems. Her goal is to apply her research interests and experiences with “big data” to novel and exciting studies that will ultimately lead to better health outcomes for patients at KPMAS.

Dr. Vupputuri is an elected Fellow of the American Heart Association (FAHA) conferred by the Council on Epidemiology and Prevention and recognized for her excellence and sustained contributions to scholarship, practice, education, and volunteer service within in the American Heart Association. She has 10+ years of research experience; has published over 50 manuscripts in peer-reviewed journals; and served as PI/site-PI/co-PI on more than 15 funded studies.

Research Interests:

Chronic disease epidemiology (cardiovascular disease, diabetes, chronic kidney disease), health services, health disparities, comparative effectiveness, medication adherence, quality of care issues

For a full list of publications, please see Dr. Vupputuri’s Curriculum Vitae.

  1. Vupputuri S, Rubenstein KB, Derus AJ, Loftus B, Horberg MA. Factors Contributing to Racial Disparities in Influenza Vaccinations. American Journal of Managed Care, submitted.
  2. Reboussin DM, Allen N, Griswold ME, Guallar E, Hong Y, Lackland DT, Miller EPR, Polonsky T, Thompson-Paul AM, Vupputuri S. A Systematic Review for the 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA /PCNA Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Hypertension. 2017 Nov 13. [Epub ahead of print]
  3. Reynolds K, Adams KF, Boudreau D, Cassidy A, Fortmann SP, Go AS, Goldberg RJ, Greenlee R, Gunter M, Gurwitz JH, Lieu T, Magid DJ, McNeal CJ, Newton KM, Novotny R, Quesenberry CP, Smith DH, Steinhubl S, Tom JO, Vupputuri S, Waring SC, Sidney S. Trends in the Incidence of Hospitalized Acute Myocardial Infarction in the Cardiovascular Research Network (CVRN), 2000-2008. Am J Med. 2016 Oct 14. pii: S0002-9343(16)31020-8.
  4. Wu B, Bell K, Kern DM, Tunceli O, Willey V, Vupputuri S, Stanford A, Kalsekar I. Understanding CKD among patients with T2DM: prevalence, temporal trends, and treatment patterns-NHANES 2007-2012. BMJ Open Diabetes Res Care. 2016 Apr 11;4(1).
  5. Smith DH, O’Keefe-Rosetti M, Owen-Smith A, Rand C, Tom J, Vupputuri S, Laws R, Waterbury A, Hankerson-Dyson D, Yonehara C, Williams A, Shneider J, Dickerson JF, Vollmer WM. Improving Adherence to Cardiovascular Therapies: An Economic Evaluation of a Randomized Pragmatic Trial. Value Health. 2016 Mar;19(2):176-84. doi: 10.1016/j.jval.2015.11.013. Epub 2016 Feb 12.
  6. Vupputuri S, Joski JJ, Whooley M, Kilpatrick R, Robinson BE, Safford MM, Yun H, Muntner P. The Association of Statin Persistence and Uncontrolled Low Density Lipid Cholesterol Among Patients at High Risk of Coronary Heart Disease in a Managed Care Organization. Am J Manag Care. 2016 Mar 1;22(3):e106-15.
  7. Smith DH, Johnson ES, Adams K, Boudreau D, Cassidy A, Fortmann SP, Greenlee RT, Gunter M, Gurwitz JH, Lieu T, Magid DJ, McNeal CJ, Reynolds K, Steinhubl SR, Thorp M, Tom JO, Vupputuri S, VanWormer JJ, Weinstein J, Go AS, Sidney S. Comparative Effectiveness of Statin Therapy in Adults with Chronic Kidney Disease and Acute Myocardial Infarction. Am J Med. 2015 Jul 10.
  8. Vollmer W, Owen-Smith A, Tom J, Laws R, Ditmer D, Smith D, Waterbury A, Schneider J, Yonehara C, Williams A, Vupputuri S, Rand C. Health Information Technology Improves Adherence to Cardiovascular Medication and Lowers LDL Cholesterol: The PATIENT Randomized Clinical Trial. Am J Manag Care. 2014 Nov;20(11 Spec No. 17):SP502-10.
  9. Vupputuri S, Hajat C, Al-Houqani M, Osman O, Sreedharan J, Zhou S, Sherman SE, Weitzman M. Midwakh/Dokha Use in the Middle East and Globally: Still Much to Learn. Tob Control. 2016 Mar;25(2):236-41.
  10. Muntner P, Yun H, Sharma P, Delzell E, Kent S, Kilgore M, Farkouh ME, Vupputuri S, Bittner V, Rosenson RS, Levitan E, Safford MM. Prior low antihypertensive medication adherence is associated with an increased risk of low adherence and discontinuation of statin medications. Am J Cardiol. 2014 Sep 15;114(6):826-31.
  1. Social Determinants of Health and Racial/Ethnic Disparities (SO HEARD) in Hypertension, Diabetes, and Chronic Kidney Disease
    Goal:
    The overall goal of this project is to conduct an in-depth assessment of racial/ethic differences in hypertension, diabetes, and chronic kidney disease by disentangling the relationship between social determinants of health and race/ethnicity.
    Funder:
    Social Needs Network for Evaluation and Translation
    Role: Co-Primary Investigator
  2. Impact of Coronavirus Disease 2019 on Cardiovascular Care: Collateral Damage from a Pandemic
    Goal:
    This study examines characteristics of the COVID-19 patient population and factors associated with mortality especially in high-risk subgroups.  Further the project assesses trends in cardiovascular hospitalization rates prior to and during the COVID-19 pandemic.
    Funder:
    Garfield Memorial Fund
    Role: Co-Primary Investigator
  3. Cohort Study of Patients with Disorder of Sex Development (DSD)
    Goal:
    The goal of this study is to f=develop and validate an electronic health record-based cohort of patients with DSD, across 3 large health systems and describe clinical characteristic and pathways of care.  We will also compare DSD quality of care indicators against actual DSD management delivered.
    Funder:
    NICHD
    Role:
    Co-Investigator/Site Primary Investigator
  4. Using Values Affirmation to Reduce the Effects of Perceived Discrimination on Hypertension Disparities
    Goal:
    This pragmatic trail examines the effect of intervening on perceived stereotype threat on hypertension management by testing a values affirmation intervention, across 3 diverse health systems.  The primary outcome is change in adherence to antihypertensive therapies with the secondary outcome of change in blood pressure.
    Funder:
    NIH/NHLBI
    Role:
    Co-Investigator/Site Primary Investigator
  5. HbA1c Variability and Health Outcomes Among Patients with Diabetes
    Goal: The purpose of this study is to develop a new quality measure for patients with diabetes, beyond just HbA1c alone, to better identify those at risk for diabetes complications and mortality.
    Funder:
    NIDDK
    Role:
    Site Primary Investigator
  1. January 2015, Invited presentation: Kaiser Permanente Mid-Atlantic States, Mid-Atlantic Permanente Research Institute, Rockville, MD. “Big Data and Chronic Disease Research”.
  2. May 2013, Speaker/Host: Health Authority of Abu Dhabi, Department of Chronic Diseases, Abu Dhabi, UAE. “Asthma Guidelines Training Workshop” (Continuing Medical Education Workshop: 6.25 CME credits, 100 participants).
  3. April/May 2013, Speaker/Host: Health Authority of Abu Dhabi, Section of Cardiovascular and Metabolic Disorders, Abu Dhabi, UAE. “Training Workshop on the Weqaya Screening Programme” (Training of Weqaya facility clinicians and staff, 30 participants).
  4. March 2013, Guest speaker: Diabetes Complications Continuing Medical Education (CME) Workshop, Abu Dhabi, UAE. (Workshop sponsored by Pfizer).
  5. November 2012, Guest speaker: Health Authority of Abu Dhabi, Department of Cardiovascular and Metabolic Disorders, Abu Dhabi, UAE. “Training Workshop on the Weqaya Cardiovascular Screening Programme” (Training of Weqaya facilities).